Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2011

View Archived Issues

Updated data disclosed from RADIANT-2 and -3 trials of everolimus in neuroendocrine tumors

PEP-02 shows clinical benefit in pancreatic and gastric cancer

Targeting of CD44 by miRNA-34a suppresses regeneration and metastatic potential of prostate CSCs

New antiviral agents claimed with activity against HAdV-37

European scientists develop new compounds targeting negative-sense ssRNA viruses

Dasatinib is not active in previously treated metastatic colorectal cancer

Antibodies against Glo-3A as a biomarker of celiac disease

Merck & Co. discloses new orexin OX2 receptor antagonists

Novel flourine-containing oligopeptides presented by Harvard College

Novartis develops novel PI3K-alpha inhibitors

Bristol-Myers Squibb offers update on fourth quarter 2010

New inhibitors claimed of RAC-alpha serine/threonine-protein kinase phosphorylation

Hutchison MediPharma begins phase I trial of fruquintinib in China

Oragenics plans second phase I trial of SMaRT replacement therapy

Phase IIb follow-up data show efficacy of KUR-111 in bone regeneration

Alexion acquires Taligen Therapeutics and expands portfolio

FDA sets PDUFA date for Transcept's Intermezzo NDA resubmission

Eisai receives complete response letter regarding NDA for new AcipHex formulation

EMA confirms eligibility of Omeros' OMS-103HP for centralized marketing application

BioMarin begins phase III trial of N-acetylgalactosamine 6-sulfatase in MPS IVA

Enrollment begins in phase II CP-4126 trial in gemcitabine-refractory pancreatic cancer

ToleroMune cat allergy T-cell vaccine shows efficacy in phase II trial

Lixisenatide demonstrates noninferiority to exenatide in phase III GetGoal-X trial

Rockwell Medical secures participation of two U.S. dialysis companies in phase III SFP trials

FDA requests additional trial of Contrave

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...